THERAPY DOSSIER · th-e6e877cf35ae

MDM2 inhibition (pharmacological inhibitor; MDM2 shRNA and AdMDM2 used in vitro)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32856486 ↗2020Reported benefit

MDM2 inhibition improves cisplatin-induced renal injury in mice via inactivation of Notch/hes1 signaling pathway.

MouseChemical/toxinC57BL/6male

Model: Cisplatin-induced acute renal injury by intraperitoneal injection

Cisplatin raised creatinine, blood urea nitrogen, urinary cystatin C, NGAL and albumin-to-creatinine ratio, lowered glomerular filtration rate and increased tubular injury scores, MDM2, N1ICD, Hes1 and cleaved caspase-3 with a fall in the Bcl-2/Bax ratio. MDM2 inhibition improved these cisplatin-in…

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…